PMID- 32670062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in 
      Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis.
PG  - 941
LID - 10.3389/fphar.2020.00941 [doi]
LID - 941
AB  - PURPOSE: We conducted a systematic review and meta-analysis to determine the 
      effectiveness and safety of anti-tumor necrosis factor-alpha (TNF-alpha) agents in 
      the treatment of Behcets' disease (BD)-associated uveitis. METHOD: Three 
      electronic databases, Embase, MEDLINE, and the Cochrane Library, were searched 
      for eligible papers focusing on the anti-TNF-alpha agents treatment in BD-associated 
      uveitis with at least 6 months follow-up time. A systematic review and 
      meta-analysis was conducted on selected papers with appropriate clinical and 
      methodological homogeneity. The effectiveness outcomes included inflammation 
      remission, visual acuity (VA) improvement, central macular thickness (CMT) 
      decrease, corticosteroid (CS)-sparing effects, and the safety outcomes included 
      minor and severe drug-related adverse events (AEs). RESULT: From Jan 2010 to Dec 
      2019, there were 504 records produced in total, in which 18 clinical trials were 
      selected for meta-analysis (15 trials were retrospective studies, and 3 were 
      prospective studies). The number of patients in each study ranged from 11 to 163 
      and the mean follow-up time from 0.9 to 6.44 years. During the follow-up, the 
      pooled inflammation remission rate was 68% with a 95% confidence interval (CI) of 
      0.59-0.79, VA improvement rate was 60% (95% CI 0.47-0.77), CMT decrease was 
      112.70 mum (95% CI 72.8-153.0 mum). The proportions of patients who had 
      CS-suspended and CS-tapered reached 38% (95% CI 0.23-0.65) and 34% (95% CI 
      0.16-0.70), respectively. The severe AEs were reported but not common, which 
      included severe infusion reactions, pneumonia, bacteremia, tuberculosis, 
      melanoma, and lymphoma. CONCLUSION: Anti-TNF-alpha agents treatment has high 
      effectiveness including efficient inflammation remission, satisfactory VA 
      improvement, obvious CMT reduction, and significant CS-sparing effects. Although 
      some drug-related AEs were reported, the incidence of severe AEs was acceptable. 
      Anti-TNF-alpha agents treatment is a promising option for controlling BD-associated 
      uveitis.
CI  - Copyright (c) 2020 Hu, Huang, Yang, Chen, Su and Liang.
FAU - Hu, Yunwei
AU  - Hu Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Huang, Zhaohao
AU  - Huang Z
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Yang, Shizhao
AU  - Yang S
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Chen, Xiaoqing
AU  - Chen X
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Su, Wenru
AU  - Su W
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Liang, Dan
AU  - Liang D
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20200624
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7327708
OTO - NOTNLM
OT  - Behcets' disease-associated uveitis
OT  - adverse events
OT  - anti-TNF-alpha
OT  - central macular thickness decrease
OT  - corticosteroid-sparing effect
OT  - inflammation remission rate
OT  - meta-analysis
OT  - visual acuity improvement
EDAT- 2020/07/17 06:00
MHDA- 2020/07/17 06:01
PMCR- 2020/06/24
CRDT- 2020/07/17 06:00
PHST- 2020/03/16 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2020/07/17 06:01 [medline]
PHST- 2020/06/24 00:00 [pmc-release]
AID - 10.3389/fphar.2020.00941 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jun 24;11:941. doi: 10.3389/fphar.2020.00941. eCollection 
      2020.